502095737 10/16/2012

PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Pierre-Henri Storck	09/20/2012
Jean-Damien Charrier	09/20/2012
Alistair Rutherford	09/20/2012
Michael Paul Mortimore	09/20/2012
Somhairle MacCormick	09/20/2012
Ronald Marcellus Alphonsus Knegtel	09/24/2012
Steven John Durrant	09/20/2012

RECEIVING PARTY DATA

Name:	Vertex Pharmaceuticals (Europe) Limited
Street Address:	88 Milton Park
City:	Abingdon, Oxfordshire
State/Country:	UNITED KINGDOM
Postal Code:	OX14 4RY

PROPERTY NUMBERS Total: 2

Property Type	Number
Application Number:	13531467
PCT Number:	US2012043897

CORRESPONDENCE DATA

Fax Number: 6174446483

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 617-444-6100

Email: diana_decaro@vrtx.com

Correspondent Name: Vertex Pharmaceuticals Incorporated

Address Line 1: 130 Waverly Street

Address Line 4: Cambridge, MASSACHUSETTS 02139

ATTORNEY DOCKET NUMBER: VPI/11-126 US/WO PATENT

502095737 REEL: 029135 FRAME: 0272

13531467

00 085 HD

NAME OF SUBMITTER:	Diana DeCaro	
Total Attachments: 11		
source=11-126US_Executed_Assignment_lr	nvs_to_Vertex_Europe#page1.tif	
source=11-126US_Executed_Assignment_Ir	nvs_to_Vertex_Europe#page2.tif	
source=11-126US_Executed_Assignment_Invs_to_Vertex_Europe#page3.tif		
source=11-126US_Executed_Assignment_Invs_to_Vertex_Europe#page4.tif		
source=11-126US_Executed_Assignment_Invs_to_Vertex_Europe#page5.tif		
source=11-126US_Executed_Assignment_Invs_to_Vertex_Europe#page6.tif		
source=11-126US_Executed_Assignment_Invs_to_Vertex_Europe#page7.tif		
source=11-126US_Executed_Assignment_lr	nvs_to_Vertex_Europe#page8.tif	
source=11-126US_Executed_Assignment_Invs_to_Vertex_Europe#page9.tif		
source=11-126US_Executed_Assignment_Invs_to_Vertex_Europe#page10.tif		
source=11-126US_Executed_Assignment_Invs_to_Vertex_Europe#page11.tif		

PATENT REEL: 029135 FRAME: 0273

ASSIGNMENT

We,

- (1) Pierre-Henri Storck, of Abingdon, Oxfordshire, United Kingdom;
- (2) Jean-Damien Charrier, of Grove, Wantage, Oxfordshire, United Kingdom;
- (3) Alistair Rutherford of Abingdon, Oxfordshire, United Kingdom;
- (4) Michael Paul Mortimore, of Burford, Oxfordshire, United Kingdom;
- (5) Somhairle MacCormick, of Reading, Berkshire, United Kingdom;
- (6) Ronald Marcellus Alphonsus Knegtel, of Abingdon, Oxfordshire, United Kingdom; and
- (7) Steven John Durrant, of Abingdon, Oxfordshire, United Kingdom, for good and valuable consideration, receipt of which is hereby acknowledged, have assigned, sold and transferred to, by virtue of our agreement with Vertex Pharmaceuticals (Europe) Limited, and do hereby assign, sell and transfer to, Vertex Pharmaceuticals (Europe) Limited, a company registered in England and Wales under registered number 02907620 and having an office and a place of business at 88 Milton Park, Abingdon, Oxfordshire OX14 4RY U.K., its successors and assigns, all hereinafter referred to as the ASSIGNEE:
- (1) the entire right, title and interest in all countries throughout the world in and to any and all of my/our inventions, and discoveries disclosed in:
- (a) the application for United States Letters Patent entitled: COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE, and filed in the United States Patent and Trademark Office on June 22, 2012, under Application Number 13/531,467, including any renewals, revivals, reissues, reexaminations, extensions, continuations, and divisions thereof, and any substitute applications therefor, and/or
- (b) the International Patent Application entitled: COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE, filed under the Patent Cooperation Treaty in the United States Receiving Office on June 22, 2012, under Application No. PCT/US12/043897, and designating all countries, including any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof, and any substitute applications therefor;
- (2) the full and complete right to file patent applications in the name of the ASSIGNEE, its designee, or in my/our names at the election of the ASSIGNEE or its designee, on the aforesaid inventions, discoveries and applications in any country throughout the world;

Page 1 of 11

- (3) the entire right, title and interest in and to any Letters Patent which may issue thereon in any country throughout the world, and in and to any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof; and
- (4) the entire right, title and interest in and to all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications including, but not limited to, the following priority application(s):

61/500,113	US	June 22, 2011
Application No.	Country	Filing Date
61/510,200	US	July 21, 2011
Application No.	Country	Filing Date
61/620,697	US	April 5, 2012
Application No.	Country	Filing Date

and all rights of priority in any country of the world deriving from the above-identified International Patent Application.

We hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent throughout the world to the ASSIGNEE of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by me/us had this assignment, sale and transfer not been made.

We agree, at any time, upon the request of the ASSIGNEE to execute and to deliver to the ASSIGNEE any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries or applications, and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.

We further agree at any time to execute and to deliver upon request of the ASSIGNEE such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of the ASSIGNEE under this

Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

	(1) Pierre-Henri Storck			
	Date:2&	Sept	2012	
IN WITNESS WHEREOF, I have hereunto set hand and seal Signature of witness: (1)				
Printed Name of Witness:				
this day of	Date of signing			
Signature of witness: (2)				
Printed Name of Witness:				
this day of				

Date of signing

	_ Doluell	
	(2) Jean-Damien Charr	ier
	Date:	Fept 2012
IN WITNESS WHEREOF,	I have hereunto set hand and seal	
Signature of witness: (1)		
Printed Name of Witness:		
this day of	Date of signing	
Signature of witness: (2)		
Printed Name of Witness: _	·	
this day of	Date of signing	

	Date: 25th September 2012
IN WITNESS WHER	EOF, I have hereunto set hand and seal
Signature of witness:	(1)
Printed Name of Witn	css:
this day	Date of signing.
Signature of witness:	(2)
Printed Name of Witn	ess:
this day of	of

Date of signing

(3) Alistair Rutherford

Vertex Pharmaceuticals (Europe) Limited Attorney Docket No.:VPI/11-126 US WO

	(4) Michael Paul Mortimore
	Date: 20 12 Syptember, 2017
IN WITNESS WHEREOF, I	have hereunto set hand and seal
Signature of witness: (1)	
Printed Name of Witness:	·····
this day of	Date of signing
Signature of witness: (2)	
Printed Name of Witness:	
this day of	Date of signing

Vertex Pharmaceuticals (Europe) Limited Attorney Docket No.:VPI/11-126 US WO

) · land yest	
	(5) Somhairle MacCormick	
	Date: 20-9-2012.	
IN WITNESS WHEREOF, I have hereunto set hand and seal		
Signature of witness: (1)		
Printed Name of Witness:		
this day of Date of signin		
Date of signing	lg	
Signature of witness: (2)		
Printed Name of Witness:		

Date of signing

this _____ day of __

Vertex Pharmaceuticals (Europe) Limited Attorney Docket No.: VPI/11-126 US WO

2MA Mughel

(6) Ronald Marcellus Alphonsus Knegtel

Date: 24th September 2012

IN WITNESS WHEREOF, I have hereunto set hand and seal Signature of witness: (1)

Printed Name of Witness:

this _____ day of _____.

Date of signing

Signature of witness: (2)

Printed Name of Witness:

this _____ day of _____.

Date of signing

	Vertex Pharmaceuticals (Europe) Limited Attorney Docket No.:VPI/11-126 US WO
	(7) Steven John Durrant
	Date: 20(09/2012
IN WITNESS WHEREOF, I have hereunto	set hand and seal
Signature of witness: (1)	
Printed Name of Witness:	
this day of Date of signin	ng ·
Signature of witness: (2)	
Printed Name of Witness:	

this _____ day of _____ Date of signing

ACKNOWLEDGMENT OF ASSIGNEE

Stephen L. Nesbitt

Vice President and Chief IP Counsel

VERTEX PHARMACEUTICALS INCORPORATED

Date: October 15, 2012

cana Gordon

Commonwealth of Massachusetts

County of Middlesex

On this 15th day of Ochow, 2012, before me, the undersigned notary public, personally appeared Stephen L. Nesbitt (name of document signer), proved to me through satisfactory evidence of identification which was/were: personal knowledge of identity, a driver's license, other (please identify), to be the person whose name is signed on this document, and who swore or affirmed to me that the contents of the document are truthful and accurate to the best of his/her knowledge and belief.

Notary Public

My Commission Expires:

DIANA GORDON

Notary Public
Commonwealth of Massachusetts
My Comm. Expires December 7, 2012